ImmunoGen, Inc. Announces Exercise of Over-Allotment Option
May 10 2010 - 10:15AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics, announced today
that the underwriters of its previously announced public offering
of common stock have exercised in full their option to purchase
1,350,000 shares of common stock at a public offering price of
$8.00 per share. The exercise of the over-allotment option brings
the total shares of common stock to be sold by ImmunoGen in the
offering to 10,350,000 shares. Net proceeds, after underwriting
discounts and commissions and estimated expenses, will be
approximately $77.6 million. The offering is expected to close on
or about May 12, 2010, subject to satisfaction of customary closing
conditions.
J.P. Morgan Securities Inc. is acting as the sole book-runner
for the offering and Oppenheimer & Co. Inc., RBC Capital
Markets Corporation, Cantor Fitzgerald & Co. and Morgan Joseph
& Co. Inc. are acting as co-managers.
The securities described above are being offered by ImmunoGen
pursuant to a registration statement previously filed and declared
effective by the Securities and Exchange Commission. This press
release does not constitute an offer to sell or a solicitation of
an offer to buy the securities in this offering. The offering may
be made only by means of a prospectus, copies of which may be
obtained, when available, from J.P. Morgan Securities Inc.,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, or by telephone at 1-866-803-9204.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s potent cell-killing agents
specifically to tumor targets. In addition to the Company’s product
pipeline, compounds utilizing the TAP technology are in clinical
testing through ImmunoGen’s collaborations with Genentech (a wholly
owned member of the Roche Group), sanofi-aventis, Biogen Idec and
Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in
Phase III testing being conducted by Genentech/Roche. Other
ImmunoGen collaborative partners include Bayer HealthCare and
Amgen.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the public offering. A
review of these risks can be found in ImmunoGen’s Annual Report on
Form 10-K for the fiscal year ended June 30, 2009 and other reports
filed with the Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024